ОЦЕНКА РИСКА КАРДИОВАСКУЛЯРНОЙ ПАТОЛОГИИ У БОЛЬНЫХ С ПСОРИАТИЧЕСКИМ АРТРИТОМ
Abstract
Псориатический артрит (ПсА) — хроническое воспалительное ревматическое заболевание, которым страдают 0,19% населения Европы [1]. С 2016 года рекомендации Европейской кардиологической ассоциации включают аутоиммунные воспалительные заболевания в качестве неотъемлемого сердечно-сосудистого риска (CСР) [2]. Как и в случае с ревматоидным артритом (РА) [3, 4], многие исследования показали увеличение сердечно-сосудистой смертности и заболеваемости [4, 6] и более традиционных CСЗ у пациентов с ПсА [5-10]. Поэтому контроль CСР имеет важное значение. Это подтверждается снижением сердечно-сосудистых заболеваниях (CСЗ) у пациентов с РА и ПсА, получавших лечение статинами [11, 12].
References
1. Stolwijk C, van Onna M, Boonen A, van Tubergen A. The global prevalence of spondyloarthritis: a systematic review and meta-regression analysis. Arthritis Care Res (Hoboken). (2015). [Epub ahead of print]. doi: 10.1002/acr. 22831
2. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European association for cardiovascular prevention & rehabilitation (EACPR). Eur Heart J. (2016) 37:2315–81. doi: 10.1093/ eurheartj/ehw106
3. Kamolidinovna T. Z., Zikriyaevna S. G. RISK FACTORS AND FEATURES OF CORONARY HEART DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS //JOURNAL OF BIOMEDICINE AND PRACTICE. – 2022. – Т. 7. – №. 6.
4. Ogdie A, Yu Y, Haynes K, Love TJ, Maliha S, Jiang Y, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. (2015) 74:326–32. doi: 10.1136/annrheumdis-2014-205675
5. Zikriyaevna S. G., Kamolidinovna T. Z. Stratification of Cardiovascular Risk in Patients with Rheumatoid Arthritis //Telematique. – 2023. – Т. 22. – №. 01. – С. 1114-1119.
6. Gulati AM, Semb AG, Rollefstad S, Romundstad PR, Kavanaugh A, Gulati S, et al. On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Trøndelag health study. Ann Rheumat Dis. (2016) 75:819–24. doi: 10.1136/annrheumdis-2014- 206824
7. Таирова З. К., Шодикулова Г. З. Шоназарова НХ REVMATOID ARTRIT BILAN KASALLANGAN BEMORLARDA KOMORBID KASALLIKLARNING UCHRASH CHASTOTASI //Журнал кардиореспираторных исследований. – 2022. – Т. 3. – №. 4.
8. Verhoeven F, Prati C, Demougeot C, Wendling D. Cardiovascular risk in psoriatic arthritis, a narrative review. Joint Bone Spine. (2020) 87:413–8. doi: 10.1016/j.jbspin.2019.12.004
9. Ramírez J, Azuaga-Piñango AB, Celis R, Cañete JD. Update on cardiovascular risk and obesity in psoriatic arthritis. Front Med. (2021) 8:742713. doi:
10. 3389/fmed.2021.742713 10. Galarza-Delgado DA, Azpiri-Lopez JR, Colunga-Pedraza IJ, GuajardoJauregui N, Rodriguez-Romero AB, Lugo-Perez S, et al. Cardiovascular risk reclassification according to six cardiovascular risk algorithms and carotid ultrasound in psoriatic arthritis patients. Clin Rheumatol. (2021) [Epub ahead of print]. doi: 10.1007/s10067-021-06002-0
11. Kitas GD, Nightingale P, Armitage J, Sattar N, Belch JJF, Symmons DPM, et al. A multicenter, randomized, placebo-controlled trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheumatol. (2019) 71:1437–49. doi: 10.1002/art.40892 12. Oza A, Lu N, Choi HK. Survival benefit of statin use in ankylosing spondylitis and psoriatic arthritis: a general population-based cohort study [abstract]. Arthritis Rheumatol. (2016) 68 (suppl. 10) Available online at: http://acrabstracts.org/abstract/survival-benefit-of-statin-use-in-ankylosingspondylitis-and-psoriatic-arthritis-a-general-population-based-cohortstudy/ (accessed June 12, 2017).
13. Van Ganse E, Laforest L, Alemao E, Davies G, Gutkin S, Yin D. Lipidmodifying therapy and attainment of cholesterol goals in Europe: the return on expenditure achieved for lipid therapy (REALITY) study. Curr Med Res Opin. (2005) 21:1389–99. doi: 10.1185/030079905X59139
14. Ferrières J, Bongard V, Dallongeville J, Arveiler D, Cottel D, Haas B, et al. Trends in plasma lipids, lipoproteins and dyslipidaemias in French adults, 1996–2007. Arch Cardiovasc Dis. (2009) 102:293–301. doi: 10.1016/j.acvd. 2009.02.002
15. Costa L, Caso F, Ramonda R, Del Puente A, Cantarini L, Darda MA, et al. Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study. Immunol Res. (2015) 61:147–53. doi: 10.1007/s12026-014-8595-z
16. Shodikulova G. Z., Tairova Z. K. ECHOCARDIOGRAPHIC PARAMETERS IN PATIENTS WITH RHEUMATOID ARTHRITIS //СУРУНКАЛИ ЮРАК ЕТИШМОВЧИЛИГИДА COVID-19 ЎТКАЗГАН БЕМОРЛАР ЮРАК ИЧИ ГЕМОДИНАМИК КЎРСАТКИЧЛАРИНИ БАҲОЛАШ. – 2017. – Т. 69. – №. 10. – С. 176.
17. Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJL, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheumat Dis. (2017) 76:17–28. doi: 10.1136/ annrheumdis-2016-209775
18. Jamnitski A, Symmons D, Peters MJL, Sattar N, MciInnes I, Nurmohamed MT. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheumat Dis. (2013) 72:211–6. doi: 10.1136/annrheumdis-2011- 201194
19. Boyer J-F, Bongard V, Cantagrel A, Jamard B, Gottenberg J-E, Mariette X, et al. Link between traditional cardiovascular risk factors and inflammation in patients with early arthritis: results from a French multicenter cohort. Arthritis Care Res (Hoboken). (2012) 64:872–80. doi: 10.1002/acr.21623
20. Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheumat Dis. (2009) 68:460–9. doi: 10.1136/ard.2008.101964
21. Choy E, Ganeshalingam K, Semb AG, Szekanecz Z, Nurmohamed M. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford). (2014) 53:2143–54. doi: 10.1093/ rheumatology/keu224
22. Giles JT, Sattar N, Gabriel SE, Fleming T. Comparative Cardiovascular Safety of Tocilizumab Vs Etanercept in Rheumatoid Arthritis: Results of a Randomized, Parallel-Group, Multicenter, Noninferiority, Phase 4 Clinical Trial. ACR Meeting Abstracts. (2017). http://acrabstracts.org/abstract/ comparative-cardiovascular-safety-of-tocilizumab-vs-etanercept-inrheumatoid-arthritis-results-of-a-randomized-parallel-group-multicenternoninferiority-phase-4-clinical-trial/ (accessed June 6, 2017).
23. Nissen CB, Hørslev-Petersen K, Primdahl J. Cardiovascular risk profiles in a hospital-based population of patients with psoriatic arthritis and ankylosing spondylitis: a cross-sectional study. Rheumatol Int. (2017) 37:113–20. doi: 10.1007/s00296-016-3614-0
24. Rosales Alexander JL, Cantero-Hinojosa J, Salvatierra J, Magro Checa C, González-Gay MÁ, Raya Álvarez E. Cardiovascular risk assessment according to a national calibrated score risk index in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Joint Bone Spine. (2014) 81:164–8. doi: 10.1016/j.jbspin.2013. 07.008
25. Navarini L, Margiotta DPE, Caso F, Currado D, Tasso M, Angeletti S, et al. Performances of five risk algorithms in predicting cardiovascular events in patients with psoriatic arthritis: an Italian bicentric study. PLoS One. (2018) 13:e0205506. doi: 10.1371/journal.pone.0205506
26. Navarini L, Margiotta DPE, Costa L, Currado D, Tasso M, Angeletti S, et al. Performance and calibration of the algorithm ASSIGN in predicting cardiovascular disease in Italian patients with psoriatic arthritis. Clin Rheumatol. (2019) 38:971–6. doi: 10.1007/s10067-019- 04442-3
